About seller
Feration and osteoclast formation. RANK is a transmembrane molecule expressed on the surface of osteoclast precursors [6]. The NF-B and mitogen-activated protein kinase (MAPK) pathwaysare activated by RANKL binding to its receptor RANK, which induces downstream transcription factors, including c-Fos, c-Jun, and nuclear factor of activated T-cell cytoplasmic 1 (NFATc1) [7,8]. NFATc1 is considered the most important transcription factor in controlling gene expression related to osteoclast formation and function [9]. Hinokitiol, a natural tropolone-related compound, has been demonstrated to have multiple pharmacological effects, including anticancer, anti-inflammatory anti-bacterial, and anti-oxidant activities through several signaling pathways [102]. Treatment with hinokitiol suppressed osteoclast-related bone loss caused by tooth ligation [13]. However, the underlying mechanisms of action of hinokitiol on osteoclast formation and its protective effects on ovariectomy-induced bone loss are not yet known. Here, we tested the inhibitory effect of hinokitiol on RANKL-induced osteoclastogenesis and bone resorption and explored its underlying mechanism. In addition, we examined the therapeutic effect of hinokitiol on OVX-induced osteoporosis in vivo. Our current findings provide evidence for the therapeutic application of hinokitiol in treating osteoclast-mediated osteoporosis.* Corresponding author.at; Department of Orthopedics, Shaoxing People's Hospital (Shaoxing Hospital, Zhejiang University School of Medicine), Shaoxing, Zhejiang 312000, China. E-mail address: doctor120hotmail.com (Y. Qian). https://doi.org/10.1016/j.intimp.2021.107619 Received 4 February 2021; Received in revised form 25 March 2021; Accepted 25 March 2021 Available online 5 April 2021 1567-5769/2021 Elsevier B.V. Anti-payload Antibodies reserved.Y. Wang et al.International Immunopharmacology 96 (2021)2. Materials and methods 2.1. Materials Hinokitiol was purchased from MedChemExpress (New Jersey, USA) and dissolved in dimethyl sulfoxide (DMSO) and stored at a concentration of 100 mM. Alpha-modified minimal essential medium (-MEM), penicillin/streptomycin, and fetal bovine serum (FBS) were obtained from Gibco (Thermo Fisher, Waltham, MA, USA). RANKL and M CSF were obtained from R D Systems (Minneapolis, MN, USA). Cell Counting Kit-8 (CCK-8) was purchased from MedChemExpress (New Jersey, USA). Antibodies against c-Fos, p-JNK, JNK, P-p38, p38, P-ERK, ERK, P-p65, p65, P-JNK, JNK, IB, and NFATc1 were purchased from Cell Signaling Technology (Danvers, MA, USA) and used at a 1:1000 dilution. All other reagents were obtained from Sigma-Aldrich (St. Louis, MO, USA) unless otherwise stated. 2.2. Cell culture All animal experiments were performed according to the National Institutes of Health Guide for Care and Use of Laboratory Animals (NIH publication number 853, revised 1996) and approved by the Animal Ethical Committee of Shaoxing People's Hospital, Shaoxing, Zhejiang Province, China (approval number 202000). Primary mouse bone marrow macrophages (BMMs) were isolated from the bone marrow of 6week-old C57BL/6 mice and flushed out from the tibias and femurs with culture medium. BMM cells were incubated at 37 C with 5 CO2 in complete -MEM with 10 FBS, 1 penicillin/streptomycin, and 25 ng/ mL M CSF. The medium was replaced every two days until the cells reached 90 confluence. 2.3. Cell-viability assay To evaluate the cytotoxic effects of hinokitiol on BMMs and MC3T3E1 cells, CCK-8 assays.